Iovance Biotherapeutics Stock News

Bargain-hunting investors have good reason to be tempted, but a steep sell-off alone isn't enough of a bullish argument.

Bargain-hunting investors have good reason to be tempted, but a steep sell-off alone isn't enough of a bullish argument.

SAN CARLOS, Calif., Jan. 21, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today ann

TIL Therapy was Successfully and Consistently Manufactured from Cryopreserved Tumor Samples Shipped from Australia

TIL Therapy was Successfully and Consistently Manufactured from Cryopreserved Tumor Samples Shipped from Australia

SAN CARLOS, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today ann

SAN CARLOS, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA ), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that Fred Vogt, PhD, Esq., Interim Chief Executive Officer, President and General Counsel of Iovance, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 7:30 a.m. ET. The live and archived webcasts of the presentation will be available in the Investors section of the Iovance website at http://ir.iovance.com . About Iovance Biotherapeutics, Inc. Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system''s ability to recognize and destroy diverse cancer cells in each patient. Our lead late-stage TIL product candidate, lifileucel for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer.

SAN CARLOS, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today annou

SAN CARLOS, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today ann

Strs Ohio cut its stake in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 32.3% in the 3rd quarter, HoldingsChannel reports. The fund owned 105,000 shares of the biotechnology companys stock after selling 50,000 shares during the quarter. Strs Ohios holdings in Iovance Biotherapeutics were worth $2,589,000 at the end of the most recent quarter. A []

SAN CARLOS, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today ann

SAN CARLOS, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today annou

Cubist Systematic Strategies LLC cut its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 98.9% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,042 shares of the biotechnology companys stock after selling 97,600 shares during the quarter. Cubist Systematic Strategies []

Even a good year for stocks has its share of high-flyers that have turned into losers — or buying opportunities.

SAN CARLOS, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today ann